For the year ending 2025-12-31, AMPH had $18,568K increase in cash & cash equivalents over the period. $121,233K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net revenues | 719,887 |
| Payroll expense | 191,787 |
| Materials and supplies | 43,314 |
| Clinical trials expense | 3,038 |
| Depreciation and amortization expense | 56,695 |
| Stock-based compensation expense | 27,277 |
| Consulting and outside services expense | 39,771 |
| Advertising and promotional expense | 13,138 |
| Other segment items | 204,441 |
| Interest income | 8,679 |
| Interest expense | 25,481 |
| Income tax provision | 25,530 |
| Net income | 98,094 |
| Loss on disposal of assets | -39 |
| Loss (gain) on interest rate swaps and foreign currency transactions, net | -2,492 |
| Depreciation of property, plant, and equipment | 31,647 |
| Amortization of intangible assets | 25,048 |
| Operating lease right-of-use asset amortization | 6,506 |
| Amortization of discounts, premiums, and debt issuance costs | 3,355 |
| Share-based compensation expense | 27,277 |
| Changes in reserve for uncertain tax positions | -1,032 |
| Changes in deferred taxes, net | -28,660 |
| Accounts receivable, net | 6,367 |
| Inventories | 21,063 |
| Prepaid expenses and other assets | 3,530 |
| Income tax refunds, deposits, and payable, net | 24,843 |
| Operating lease liabilities | -5,609 |
| Accounts payable and accrued liabilities | -4,559 |
| Net cash provided by operating activities | 156,115 |
| Purchases and construction of property, plant, and equipment | 34,882 |
| Purchase of intangible assets | 2,250 |
| Purchase of investments | 119,130 |
| Maturity of investments | 90,291 |
| Deposits and other assets | 4,361 |
| Net cash used in investing activities | -70,332 |
| Proceeds from equity plans, net of withholding tax payments | 2,855 |
| Purchase of treasury stock | 75,586 |
| Debt issuance costs | 687 |
| Proceeds from borrowing under lines of credit | 6,216 |
| Principal payments on long-term debt | 223 |
| Net cash provided by (used in) financing activities | -67,425 |
| Effect of exchange rate changes on cash | 210 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 18,568 |
| Cash, cash equivalents, and restricted cash at beginning of period | 151,844 |
| Cash, cash equivalents, and restricted cash at end of period | 170,412 |
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)